Catalyst Pharmaceuticals June 15th Short Interest Update

Catalyst Pharmaceuticals (NASDAQ:CPRX) has witnessed a drop of 4.1% or 198,212 shares in its short figure. The short interest diminution took it from 4,868,040 on May 31,2016 to 4,669,828 on June 15,2016. In terms of floated shares, the short interest was calculated to be 6.7%. The days to cover are 5 given that the daily volume averaged 923,764 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Catalyst Pharmaceuticals (NASDAQ:CPRX): The stock opened at $0.79 on Friday but the bulls could not build on the opening and the stock topped out at $0.86 for the day. The stock traded down to $0.75 during the day, due to lack of any buying support eventually closed down at $0.79 with a loss of -9.77% for the day. The stock had closed at $0.88 on the previous day. The total traded volume was 8,328,270 shares.

The company shares have dropped -79.80% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $5.80 and the one year low was seen on Apr 26, 2016. The 50-Day Moving Average price is $0.67 and the 200 Day Moving Average price is recorded at $1.35.

Catalyst Pharmaceuticals (NASDAQ:CPRX) has climbed 5.29% in the past week and advanced 30.16% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 7.04% and the outperformance has advanced to 34.1% for the last 4 weeks period.

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. Firdapse is used for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). CPP-115 is used for the treatment of addiction and epilepsy. CPP-109 is used to treat addiction. The Company is conducting a Phase III trial to determine the safety and efficacy of Firdapse in the treatment of LEMS. CPP-115 has been granted Orphan Drug Designation by the food and drug administration (FDA) for the treatment of infantile spasms and Orphan Medicinal Product Designation in the European Union, for West syndrome (a form of infantile spasms).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.